Refine Search
(2)
(2)
(3)
(3)

Dermatology: Pharma’s Latest Focus

Dermatology has recently become a point of interest for pharmaceutical innovation. Considering the total number of clinical trials in Phase II, III, and Pre-Registration stages, the already-crowded plaque psoriasis market remains the industry’s top favourite dermatology indication. Following closely behind is atopic dermatitis (AD), another hotbed of clinical development marked by the presence of interleukin (IL) inhibitors and oral Janus kinase (JAK) inhibitors in late-stage development. The third indication in line is acne vulgaris, a market that has historically lagged behind in innovation but now boasts of a number of first-in-class therapies in development.

Acne Vulgaris: Epidemiology Forecast to 2026

  • $3,995
  • March 2018
Add to Basket Quick View Add to Saved List

Acne vulgaris (acne) is a chronic inflammatory skin disease that presents as open or closed comedones and inflammatory lesions. Comedones include blackheads and whiteheads, while inflammatory lesions include papules, pustules, or cysts. Acne is...

Acne Vulgaris – Opportunity Analysis and Forecasts to 2026

  • $10,995
  • March 2018
Add to Basket Quick View Add to Saved List

Acne vulgaris (acne) is currently one of the most common and well-established dermatology conditions, affecting around 90% of the world’s population at some point in their lifetime. The disease is a chronic, inflammatory dermatological conditio...

Atopic Dermatitis Global Clinical Trials Review, H1, 2017

  • $2,500
  • May 2017
Add to Basket Quick View Add to Saved List

GlobalData's clinical trial report, “Atopic Dermatitis Global Clinical Trials Review, H1, 2017" provides an overview of Atopic Dermatitis clinical trials scenario. This report provides top line data relating to the clinical trials on A...

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • April 2016
Add to Basket Quick View Add to Saved List

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Altho...

PharmaPoint: Atopic Dermatitis – Global Drug Forecast and Market Analysis to 2024

  • $10,995
  • November 2015
Add to Basket Quick View Add to Saved List

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for ...